Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Enlivex ( (ENLV) ).
Enlivex Ltd., a quality longevity company listed on Nasdaq and headquartered in Nes‑Ziona, Israel, combines development of its Allocetra™ immunotherapy for age‑related inflammatory conditions with a treasury strategy tied to the Rain decentralized prediction markets protocol. This dual model is designed to align long‑term shareholder value with growth in both the longevity therapeutics market and the prediction markets ecosystem.
On March 25, 2026, Enlivex reported full‑year 2025 net income of $1.23 billion and diluted EPS of $25.48, driven primarily by unrealized appreciation in its treasury and treasury‑related derivative assets. As of December 31, 2025, the company held $2.31 billion in treasury and related derivatives, $1.93 billion in shareholders’ equity, and $30 million in cash, cash equivalents and short‑term digital‑asset investments, underscoring how its innovative treasury strategy materially boosted profitability while clinical programs with Allocetra™ continued to progress.
The most recent analyst rating on (ENLV) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
Spark’s Take on ENLV Stock
According to Spark, TipRanks’ AI Analyst, ENLV is a Neutral.
The score is held down mainly by weak financial performance (no revenue, ongoing losses, and persistent cash burn despite improvement) and a valuation profile dominated by negative earnings. Technicals provide partial support due to a clear uptrend, but overbought momentum readings add near-term risk.
To see Spark’s full report on ENLV stock, click here.
More about Enlivex
Enlivex Ltd. is a clinical-stage “quality longevity” company developing Allocetra™, an immunotherapy targeting inflammatory conditions of aging, with a primary focus on age‑related osteoarthritis. In parallel, it operates a prediction markets‑linked treasury strategy built around the Rain decentralized protocol on Arbitrum, giving investors exposure to both longevity therapeutics and emerging prediction markets infrastructure.
Average Trading Volume: 341,720
Technical Sentiment Signal: Sell
Current Market Cap: $261.1M
For an in-depth examination of ENLV stock, go to TipRanks’ Overview page.